BioSpace News Archive

Biorasi, a leading global full-service contract research organization, has announced the appointment of Jimmy El Hokayem, Ph.D., head of the company’s Neurology and Regenerative Medicine Center of Excellence to the Scientific Advisory Board for the Foundation for Angelman Syndrome Therapeutics.

“The Nasdaq is the premier stock exchange for biotechnology companies, and we believe that this is an opportune time for Cardiol to formally apply for an uplisting of our common shares.

The KARE clinical research study, led by Prof. Celia Morgan of the University of Exeter, was a Phase II a/b, four-armed, placebo-controlled trial assessing ketamine combined with the KARE psychotherapy in the treatment for alcohol use disorder (AUD).

AIM’s 3D microfluidic organ-on-a-chip platform more accurately mimics the human microenvironment than conventional assays.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF).

GENIXUS, a pharmaceutical company focused on transforming acute and critical care medicines, today announced the addition of two new members to its executive team: Seth Coombs joins as Chief Commercial Officer and Don Anthony J.D. Ph.D. as Executive Vice President, Global Head of Intellectual Property.

SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of percutaneous peripheral nerve stimulation for patients with recurrent low back pain who underwent a radiofrequency ablation procedure at least six months prior.

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference

Beyond Batten Disease Foundation is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease.

Healing Innovations, Inc., announced the successful completion of the first pilot for the new Rise&Walk™ InClinic technology at Shepherd Center in Atlanta, Georgia, USA.